EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Presence of IDH2 and TP53 mutations significantly reduces survival of patients with chondrosarcoma

Anne Weidlich iD, Klaus-Dieter Schaser, Tareq A Juratli, Jessica Pablik, Sven Märdian, Kathrin Hauptmann, Philipp Schwabe, Stephan Richter, Hagen Fritzsche

Cancer · 01.04.2026 · 132 (7)

DOI: 10.1002/cncr.70376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 29.03.2026. Verfasst von Anne Weidlich und 8 weiteren Autor:innen. Beteiligte Einrichtung: University Center for Orthopedics, Trauma Surgery, and Plastic Surgery, Sarcoma Center, National Center for Tumor Diseases, German Cancer Research Ce…. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Chondrosarcoma, Mutation, Tumor Suppressor Protein p53. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Sarkomstiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chondrosarcoma (CS) has a prognosis largely influenced by tumor grade. Although IDH mutations have been reported in CS, impact on patient`s survival remains controversial. This study aims to assess prognostic relevance of IDH mutations on disease‐specific survival (DSS), metastasis‐free survival (MFS), and local recurrence‐free survival (RFS), in a large cohort of CS patients.

Methods

The authors retrospectively analyzed CS samples from patients treated at two German musculoskeletal tumor centers. Tumor‐specific mutations, including IDH , TP53 , TERT promoter , and CDKN2A/B , were identified through DNA isolation and next‐sequencing. Molecular findings were correlated with oncologic outcomes to evaluate their prognostic significance.

Results

A total of 109 patients (53 females, 56 males; median age, 57 (16–89) years) were included. Tumor grades were G1/ACT (39%), G2 (41%), and G3/dedifferentiated (10%). Median follow‐up was 3.8 years with mortality of 17%. IDH mutations were detected in 59% ( IDH1 : 64%, IDH2 : 36%), with dedifferentiated CS showing highest IDH mutation rate (91%), particularly IDH2 . IDH2 ‐mutations were associated with significantly worse DSS compared to IDH –wild‐type or IDH1 ‐mutated tumors, independent of tumor grade. Specifically, IDH1 ‐ R132C mutation correlated with significantly improved DSS compared to R132G , and IDH2 ‐ R172S variant showed longest DSS and MFS, whereas IDH2 ‐ R172T was linked to significant poor outcomes. In multivariable analysis, IDH2 and TP53 mutations were independent predictors of worse survival.

Conclusion

IDH2 and TP53 mutations are enriched in dedifferentiated CS and are significant, independent predictors of adverse survival, regardless of tumor grade. These findings support IDH2 mutation status as clinically meaningful prognostic biomarker that may allow risk stratification and clinical decision‐making in CS patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseChondrosarcomaMutationTumor Suppressor Protein p53Bone NeoplasmsHumansFemaleMiddle AgedMaleAgedPrognosisAdultAged, 80 and overRetrospective StudiesAdolescentYoung Adult

Stichwörter der Autor:innen

IDH mutationIDH2TP53chondrosarcomasarcomasurvival

Substanzen

Isocitrate DehydrogenaseIDH2 protein, humanTumor Suppressor Protein p53TP53 protein, humanIDH1 protein, human

Autor:innen und Institutionen

  • University Center for Orthopedics, Trauma Surgery, and Plastic Surgery, Sarcoma Center, National Center for Tumor Diseases, German Cancer Research Center, University Hospital Carl Gustav Carus Dresden, Dresden, Germany.
  • Department of Neurosurgery, Neurooncology Center, National Center for Tumor Diseases, German Cancer Research Center, University Hospital Carl Gustav Carus Dresden, Dresden, Germany.
  • Institute of Pathology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany.
  • Center for Musculoskeletal Surgery, Charité-Berlin University Medicine, Berlin, Germany.
  • Institute of Pathology, Charité-Berlin University Medicine, Berlin, Germany.
  • Department for Trauma and Orthopedic Surgery, Center for Musculoskeletal Tumor Medicine, Vivantes Hospital Spandau, Berlin, Germany.

ORCID-Profile: Anne Weidlich

Förderung

  • Deutsche Sarkomstiftung

Zitieren

APA

Weidlich, A., Schaser, K. D., Juratli, T. A., Pablik, J., Märdian, S., Hauptmann, K., Schwabe, P., Richter, S., & Fritzsche, H. (2026). Presence of IDH2 and TP53 mutations significantly reduces survival of patients with chondrosarcoma. Cancer, 132(7). https://doi.org/10.1002/cncr.70376

Vancouver

Weidlich A, Schaser KD, Juratli TA, Pablik J, Märdian S, Hauptmann K, et al. Presence of IDH2 and TP53 mutations significantly reduces survival of patients with chondrosarcoma. Cancer. 2026;132(7). doi:10.1002/cncr.70376

BibTeX
@article{Weidlich2026,
  author = {Weidlich, Anne and Schaser, Klaus-Dieter and Juratli, Tareq A and Pablik, Jessica and Märdian, Sven and Hauptmann, Kathrin and Schwabe, Philipp and Richter, Stephan and Fritzsche, Hagen},
  title = {Presence of IDH2 and TP53 mutations significantly reduces survival of patients with chondrosarcoma},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {7},
  doi = {10.1002/cncr.70376}
}
Kostenlos starten →